{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.84","upperLimit":"1.98","value":"1.91"},{"groupId":"OG001","lowerLimit":"1.82","upperLimit":"2.0","value":"1.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Duraion of MRD-negativie disease was defined as the duration from the date of MRD negative to the date of diseae progression or date of last clinical follow up.","dispersionType":"Full Range","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nDexamethasone: Given PO","id":"OG000","title":"Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)"},{"description":"Patients receive lenalidomide PO as in Arm I.\n\nLenalidomide: Given PO","id":"OG001","title":"Arm II (Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"Patients who had MRD-negative were analyzed.","reportingStatus":"POSTED","timeFrame":"every 28 days, up to 2 years","title":"Duration of MRD-negative Disease","type":"SECONDARY","unitOfMeasure":"years"}